Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-?B-NLRP3 Inflammasome Signaling Pathway

Basit Öğe Kaydı
dc.contributor.authorAydin, Pelin
dc.contributor.authorMagden, Zeynep Berna Aksakalli
dc.contributor.authorUzuncakmak, Sevgi Karabulut
dc.contributor.authorHalici, Hamza
dc.contributor.authorAkgun, Nurullah
dc.contributor.authorMendil, Ali Sefa
dc.contributor.authorMokhtare, Behzad
dc.date.accessioned2024-10-04T18:48:21Z
dc.date.available2024-10-04T18:48:21Z
dc.date.issued2022
dc.departmentBayburt Üniversitesien_US
dc.description.abstractAim We demonstrate the effect of PDE5 inhibitors in cases of acute lung injury via the relationship between cGMP/NO and the TLR4-NF-kappa B-NLRP3 pathway. Materials and Methods This study was performed with 30 male Wistar albino rats. Lipopolysaccharide (LPS) was administered intratracheally to the rats and acute lung injury (ALI) was induced. Twelve hours after LPS administration, avanafil, prepared at suitable doses according to the body weights of the animals, was administered by oral gavage. Lung tissue samples of all groups were examined histopathologically and by immunochemical staining (IL-1 beta, iNOS, TLR4, and NF-kappa B). The iNOS, NLRP3, and IL-1B mRNA expression levels in the lung tissues were measured by RT-PCR. The left upper lobes of the rat lungs were dried at 70 degrees C for 48 h and lung water content was calculated. Result Statistically significant increases in iNOS, NLRP3, and IL-1 beta mRNA expressions were observed in the rats with ALI compared to the healthy controls (p < 0.0001). Those increased expressions were reduced at both doses of avanafil (p < 0.0001). This reduction was found to be greater at 20 mg/kg (p < 0.0001). IL-1 beta, iNOS, TLR4, and NF-kappa B immunopositivity was moderate/severe in the ALI group and mild in the group with ALI + avanafil at 20 mg/kg (p < 0.05). When the wet/dry lung ratios were calculated, a statistically significant increase was seen in the ALI group compared to the healthy rats (p < 0.05). That increase was decreased with both avanafil doses (p < 0.05). Conclusion We suggest that avanafil may prevent the progression of ALI and be effective in its treatment. We hope that this study will be supported by future clinical studies to yield a new indication for avanafil.en_US
dc.identifier.doi10.1007/s00408-022-00564-9
dc.identifier.endpage572en_US
dc.identifier.issn0341-2040
dc.identifier.issn1432-1750
dc.identifier.issue5en_US
dc.identifier.pmid36040529en_US
dc.identifier.scopus2-s2.0-85138000311en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage561en_US
dc.identifier.urihttps://doi.org/10.1007/s00408-022-00564-9
dc.identifier.urihttp://hdl.handle.net/20.500.12403/3030
dc.identifier.volume200en_US
dc.identifier.wosWOS:000847659000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofLungen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute Respiratory-Distressen_US
dc.subjectNlrp3 Inflammasomeen_US
dc.subjectNitric-Oxideen_US
dc.subjectInhibitorsen_US
dc.subjectRecognitionen_US
dc.subjectReceptorsen_US
dc.subjectPulmonaryen_US
dc.subjectFibrosisen_US
dc.titleAvanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-?B-NLRP3 Inflammasome Signaling Pathwayen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu